Fennec Pharmaceuticals Inc. (FENC)
Adherex Technologies Inc. (FENC) Reports Q2 Loss, Beats Revenue Estimates
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.2 per share a year ago.
Recent Price Trend in Adherex Technologies (FENC) is Your Friend, Here's Why
Adherex Technologies (FENC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Fennec Pharmaceuticals Inc. (FENC) Q1 2025 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Officer and Director Conference Call Participants Chase Knickerbocker - Craig Hallum Sudan Loganathan - Stevens Michael Okunewitch - Maxim Group Raghuram Selvaraju - H.C. Wainwright Operator Good morning, ladies and gentlemen.
Adherex Technologies Inc. (FENC) Reports Q1 Loss, Tops Revenue Estimates
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.41 per share a year ago.
Wall Street Analysts See an 113.25% Upside in Adherex Technologies (FENC): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 113.3% in Adherex Technologies (FENC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Down -22.15% in 4 Weeks, Here's Why Adherex Technologies (FENC) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Adherex Technologies (FENC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Fennec Pharmaceuticals Inc. (FENC) Q4 2024 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q4 2024 Earnings Conference Call March 10, 2025 8:30 AM ET Company Participants Robert Andrade - CFO Jeff Hackman - CEO and Board Member Conference Call Participants Chase Knickerbocker - Craig-Hallum Raghuram Selvaraju - H.C. Wainwright Felix Ampomah - Stephens Michael Okunewitch - Maxim Group Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings and Corporate Update Conference Call.
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue Estimates
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.56. This compares to loss of $0.10 per share a year ago.
Is the Options Market Predicting a Spike in Adherex Technologies (FENC) Stock?
Investors need to pay close attention to Adherex Technologies (FENC) stock based on the movements in the options market lately.
Fennec Pharmaceuticals Inc. (FENC) Q3 2024 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q3 2024 Earnings Conference Call November 9, 2024 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Officer and Director Conference Call Participants Chase Knickerbocker - Craig-Hallum Raghuram Selvaraju - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Third Quarter 2024 Earnings and Corporate Update Conference Call.
Adherex Technologies Inc. (FENC) Reports Q3 Loss, Misses Revenue Estimates
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.07 per share a year ago.
Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for
Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
